Literature DB >> 26365121

Low-grade risk of hypercoagulable state in patients suffering from diabetes mellitus type 2.

Barbara Ruszkowska-Ciastek1, Alina Sokup1, Tomasz Wernik1, Piotr Rhone1, Krzysztof Góralczyk1, Kornel Bielawski1, Agata Fijałkowska1, Aleksandra Nowakowska1, Elżbieta Rhone1, Danuta Rość1.   

Abstract

OBJECTIVE: Diabetes, including type 1 and type 2, is associated with the hypercoagulable state. The aim of this study is to evaluate the concentration of selected hemostatic parameters and vascular endothelial growth factor-A (VEGF-A) in diabetic subjects.
METHODS: The study was conducted in 62 patients with diabetes. Group I consisted of 27 patients having uncontrolled diabetes with microalbuminuria and Group II included 35 well-controlled diabetic patients. The control group was made up of 25 healthy volunteers. In the citrate plasma, the concentrations of tissue factor (TF), tissue factor pathway inhibitor (TFPI), thrombin-antithrombin (TAT) complexes, and D-dimer were assayed. Serum concentrations of VEGF-A, lipid profile, creatinine, and plasma fasting glucose were measured and in the versene plasma the concentration of HbA1c was determined.
RESULTS: In the patients with uncontrolled diabetes, higher concentrations of TF, TFPI, and VEGF-A were observed, as compared with the well-controlled diabetics group and the control group. A significantly lower activity of antiplasmin was reported in patients from Group I as compared with the control group. In Group I, using the multivariate regression analysis, the glomerular filtration rate was independently associated with VEGF-A and dependently associated with total cholesterol.
CONCLUSIONS: The study showed higher concentrations of TF and TFPI in the patients with uncontrolled diabetes with microalbuminuria, which is associated with rapid neutralization of the thrombin formation, since TFPI inhibits the complex of TF/VIIa/Ca(2+). The manifestation of the above suggestions is the correct TAT complexes and D-dimer, which indicates a low grade of prothrombotic risk in this group of patients, but a higher risk of vascular complications.

Entities:  

Keywords:  Angiogenesis; Diabetes; Extrinsic coagulation pathway; Glomerular filtration rate

Mesh:

Substances:

Year:  2015        PMID: 26365121      PMCID: PMC4569687          DOI: 10.1631/jzus.B1500066

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  27 in total

Review 1.  Coagulation and fibrinolysis in diabetes.

Authors:  S H Alzahrani; R A Ajjan
Journal:  Diab Vasc Dis Res       Date:  2010-09-16       Impact factor: 3.291

2.  The role of vascular endothelial growth factor in the progression of diabetic vascular complications.

Authors:  R A Mahdy; W M Nada; K M Hadhoud; S A El-Tarhony
Journal:  Eye (Lond)       Date:  2010-05-28       Impact factor: 3.775

3.  Effect of uncontrolled hyperglycemia on levels of adhesion molecules in patients with diabetes mellitus type 2.

Authors:  Barbara Ruszkowska-Ciastek; Alina Sokup; Tomasz Wernik; Zofia Ruprecht; Barbara Góralczyk; Krzysztof Góralczyk; Grażyna Gadomska; Danuta Rość
Journal:  J Zhejiang Univ Sci B       Date:  2015-05       Impact factor: 3.066

Review 4.  Tissue factor and cardiovascular disease: quo vadis?

Authors:  Alexander Breitenstein; Felix C Tanner; Thomas F Lüscher
Journal:  Circ J       Date:  2009-12-08       Impact factor: 2.993

5.  Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease.

Authors:  Delma Veron; Kimberly J Reidy; Claudia Bertuccio; Jason Teichman; Guillermo Villegas; Juan Jimenez; Wa Shen; Jeffrey B Kopp; David B Thomas; Alda Tufro
Journal:  Kidney Int       Date:  2010-03-10       Impact factor: 10.612

6.  Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients.

Authors:  Jiangzi Yuan; Qunying Guo; Abdul Rashid Qureshi; Björn Anderstam; Monica Eriksson; Olof Heimbürger; Peter Bárány; Peter Stenvinkel; Bengt Lindholm
Journal:  Nephrol Dial Transplant       Date:  2013-07-04       Impact factor: 5.992

7.  Inflammation and thrombosis in diabetes.

Authors:  Katharina Hess; Peter J Grant
Journal:  Thromb Haemost       Date:  2011-04-11       Impact factor: 5.249

8.  Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes.

Authors:  Trine B Opstad; Alf Age Pettersen; Thomas Weiss; Harald Arnesen; Ingebjørg Seljeflot
Journal:  Thromb J       Date:  2010-05-05

Review 9.  The role of tissue factor and tissue factor pathway inhibitor in health and disease states.

Authors:  Louis A DelGiudice; George A White
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2009-02

10.  Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus.

Authors:  Peter Kubisz; Peter Chudý; Ján Stasko; Peter Galajda; Pavol Hollý; Robert Vysehradský; Marián Mokán
Journal:  Acta Diabetol       Date:  2009-05-13       Impact factor: 4.280

View more
  4 in total

1.  Metabolic syndrome is associated with increased risk of short-term post-procedural complications after carotid artery stenting.

Authors:  Shuyang Dong; Zeyan Peng; Yong Tao; Yinchao Huo; Huadong Zhou
Journal:  Neurol Sci       Date:  2017-08-07       Impact factor: 3.307

2.  Tissue factor levels in type 2 diabetes mellitus.

Authors:  Prashilla Soma; Albe C Swanepoel; Janette Bester; Etheresia Pretorius
Journal:  Inflamm Res       Date:  2017-02-28       Impact factor: 4.575

3.  Effect of circulating tissue factor on hypercoagulability in type 2 diabetes mellitus studied by rheometry and dielectric blood coagulometry.

Authors:  Isao Uchimura; Makoto Kaibara; Masayuki Nagasawa; Yoshihito Hayashi
Journal:  Biorheology       Date:  2016       Impact factor: 1.875

4.  Clinical Significance of Hemostatic Parameters in the Prediction for Type 2 Diabetes Mellitus and Diabetic Nephropathy.

Authors:  Lianlian Pan; Yali Ye; Mingyi Wo; Danni Bao; Fengjiao Zhu; Maoliang Cheng; Xiuwen Ni; Xianming Fei
Journal:  Dis Markers       Date:  2018-02-04       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.